License agreement

Antibodies
#License agreement #Roche #T cell engagers #Therapeutic Antibodies #Zymeworks

Roche licenses Zymeworks’ trispecific T cell engager targeting DLL3

Zymeworks has entered into a global license and collaboration agreement with Roche for the research, development and commercialisation of ZW209, a T cell engager targeting DLL3.  Under the agreement, Zymeworks is eligible to receive an upfront payment of $55 million, a $40 million payment upon initiation of the Phase Ib… Read More

#Business & Investment #News

#Genentech #License agreement #Neuroscience #Parkinson's

Genentech licenses enzyme replacement therapy for Parkinson’s

Alector has granted Genentech worldwide rights to develop and commercialise its AL050 programme, a brain-penetrant engineered glucocerebrosidase (GCase) enzyme replacement therapy (ERT).  As part of the deal, Alector will receive a $100 million upfront payment, with potential for up to $1.17 billion in additional milestone payments, as well as tiered… Read More

#Business & Investment #News

Kidney on a chip technology
#Europe #Hansa Biopharma #License agreement #MENA

Hansa closes €115m licensing transaction for Idefirix 

Hansa Biopharma has closed a €115 million licensing transaction with SERB Pharmaceuticals for its kidney transplant drug in Europe and MENA.  Idefirix is a first-in-class treatment that specifically targets and cleaves all classes of immunoglobulin G (IgG) antibodies within two to six hours. It is conditionally authorised by the European Commission… Read More

#Business & Investment #News

Adenovirus
#AAV #Alexion #Drug delivery #Gene therapy #JCR Pharmaceuticals #License agreement

JCR and Alexion deal boosts AAV-based gene therapy

JCR Pharmaceuticals and Alexion, AstraZeneca Rare Disease, have entered into a license agreement for JCR’s JUST-AAV capsids to develop genomic medicines.  JUST-AAV encompasses a range of vector types optimised for various target tissues—including liver-sparing, muscle-targeting, and brain-targeting variants—to expand the potential of AAV-based gene therapy.  Under the terms of the… Read More

#Business & Investment #News

#Collaboration #Immunology #License agreement #Monte Rosa Therapeutics #Novartis

Novartis and Monte Rosa partner on molecular glue degraders

Monte Rosa Therapeutics and Novartis have agreed a global license agreement to advance VAV1 molecular glue degrader-based medicines (MGDs). The deal includes MRT-6160, which is currently in an ongoing Phase I study for immune-mediated conditions. Under the terms of the agreement, Novartis will obtain exclusive worldwide rights to develop, manufacture… Read More

#Business & Investment #News

T cell receptor
#Adaptimmune Therapeutics #Cell therapy #Collaboration #Galapagos #License agreement #Solid tumours

Companies partner on TCR T-cell therapy for head & neck cancer

Adaptimmune Therapeutics and Galapagos have entered into a clinical collaboration agreement to develop Adaptimmune’s TCR T-cell therapy for head and neck cancer and other potential solid tumours. Under the terms of the agreement, Adaptimmune will receive an upfront exclusivity payment of $70 million, plus $15 million… Read More

#Cancer Research #News

Plant-based concept
#Botanical #Jaguar Health #License agreement #Neuroscience #Plant-based #Schizophrenia

Jaguar Health out-licenses plant-based drug for schizophrenia

Jaguar Health’s out-licensing agreement with Magdalena Biosciences to develop novel, natural prescription medicines derived from plants for mental health indications, has been expanded. The agreement now includes the ethnobotanical know-how related to development of a prescription drug compound from a specified medicinal plant for possible schizophrenia and psychoses indications and… Read More

#Business & Investment #News

#Arvinas #License agreement #Novartis #Prostate cancer #PROTAC #Protein degradation

Novartis buys Arvinas’ prostate cancer protein degrader for $150m

Biotechnology company Arvinas has entered into an exclusive strategic license agreement with Novartis for ARV-766, Arvinas’ second generation PROTAC androgen receptor (AR) degrader for patients with prostate cancer. The transaction also includes an asset purchase agreement for the sale of Arvinas’ preclinical AR-V7 programme, a splice variant of the AR. Read More

#Business & Investment #News

CRISPR-Cas9
#CRISPR-Cas9 #ERS Genomics #License agreement #StemSight

CRISPR/Cas9 tech agreement for corneal blindness cell therapies  

ERS Genomics, a CRISPR/Cas9 licensing company, and StemSight, a biotechnology company developing stem cell based therapies for corneal blindness, have entered a non-exclusive CRISPR/Cas9 license agreement. The agreement grants StemSight access to ERS’ CRISPR/Cas9 patent portfolio.  StemSight is a preclinical biotechnology company developing off-the-shelf cell therapies for… Read More

#News

Business agreement
#Colorectal cancer #Inspirna #License agreement #Merck #Oncology #Phase II trial

Merck expands colorectal cancer portfolio with ompenaclid

Merck has agreed a deal with Inspirna for ompenaclid (RGX-202), a first-in-class oral inhibitor of the creatine transport channel SLC6A8 and SLC6A8-targeting follow-on compounds. Ompenaclid is currently being evaluated in a Phase II study for the second-line treatment of RAS-mutated (RASmut) advanced or metastatic colorectal cancer (mCRC). “Over the past… Read More

#Business & Investment #News

Cancer Abnormal Cells Nucleus Genetic Division Infection Microscope
#Antibody drug conjugate (ADC) #Biocytogen Pharmaceuticals #License agreement #Pheon Therapeutics #Therapeutic Antibodies

Licence agreement to develop ADCs for hard-to-treat cancers 

Pheon Therapeutics, an antibody drug conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, has entered an exclusive licence agreement with Biocytogen Pharmaceuticals, a global biotech company focused on the discovery of novel antibody therapeutics.   Under the terms of the agreement, Pheon… Read More

#News

#Collaboration #Drug development #Drug discovery #License agreement #Mergers and acquisitions

This week in drug discovery (8-12 May)

News round-up for 8-12 May by DDW Digital Content Editor Diana Spencer. Inspired by the relaunch of PerkinElmer’s Life Science and Diagnostics business this week as Revvity, my top five news story this week all relate to new drug discovery business developments. See below for the… Read More

#News

Handshake
#Autoimmune disease #Collaboration #License agreement #Tay Therapeutics #VYNE Therapeutics

Tay licenses oral BET inhibitor to VYNE Therapeutics

UK company Tay Therapeutics has entered into an exclusive license agreement with US biotech VYNE Therapeutics for its oral bromodomain and extra-terminal domain (BET) inhibitor TAY-B2. Tay Therapeutics out-licensed its topical pan-BET inhibitor to VYNE for £16m in upfront and milestone payments in 2021. The out-licensing of both of Tay… Read More

#Business & Investment #News

Tau proteins
#Asceneuron #Ferrer #License agreement #Neurodegenerative disorders #Neurology #Orphan drugs #Tau protein

Ferrer secures worldwide rights to PSP drug

Spanish pharma company Ferrer and Swiss biotech Asceneuron have signed a licensing agreement giving Ferrer the rights to ASN90 in progressive supranuclear palsy (PSP), an orphan, tau-related disease with a high unmet medical need.  The terms of the agreement include an upfront fee and multiple development, regulatory and commercial milestone… Read More

#Business & Investment #News

Antibody drug conjugate
#Antibodies #Antibody drug conjugate (ADC) #Collaboration #License agreement #Partnership #Precision medicine

Collaboration will combine ADC technology and precision therapeutics

Synaffix and Hummingbird Bioscience have entered into a licensing agreement that it is hoped will enable Hummingbird Bio to develop an antibody drug conjugate (ADC) programme using Synaffix technology.   Under the terms of the agreement, Synaffix will be eligible to receive up to $150 million, including upfront and milestone payments,… Read More

#Business & Investment #News

AAV gene therapy
#AAV #Animal models #CANbridge Pharmaceuticals #Cell and gene therapy #China #Gene therapy #License agreement #Muscular dystrophy

Chinese biotech company consolidates gene therapy portfolio

CANbridge Pharmaceuticals has exercised its option to secure the exclusive global rights to develop, manufacture and commercialise a novel gene therapy to treat spinal muscular atrophy (SMA) from UMass Chan Medical School.  Animal data presented in 2022 showed that the gene therapy outperformed the benchmark therapy along… Read More

#News